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Abstract
Based on remarkable success of PTH as an anabolic drug for osteoporosis, case reports of off-
label use of teriparatide (1-34 PTH) in patients with complicated fractures and non-unions are
emerging. We investigated the mechanisms underlying PTH accelerated fracture repair. Bone
marrow cells from 7 days 40cg/kg of teriparatide treated or saline control mice were cultured and
Osx and osteoblast phenotypic gene expression assessed by real time RT-PCR in these cells.
Fractured animals injected daily with either saline or 40cg/kg of teriparatide for up to 21 days
were X-rayed and histological assessment performed, as well as immunohistochemical analyses of
the Osx expression in the fracture callus. Osx, Runx2 and osteoblast or chondrocyte phenotypic
gene expression was also assessed in fracture calluses. Our data shows that Osx and Runx2 are up-
regulated in marrow-derived MSCs isolated from mice systemically treated with teriparatide.
Furthermore, these MSCs undergo accelerated osteoblast maturation compared to saline injected
controls. Systemic teriparatide treatments also accelerated fracture healing in these mice
concomitantly with increased Osx expression in the PTH treated fracture calluses compared to
controls. Collectively, these data suggest a mechanism for teriparatide mediated fracture healing
possibly via Osx induction in MSCs.
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Introduction
Osteoporosis affecting more than 20 million Americans accounts for approximately 1.5
million fragility fractures every year [Finkelstein J.S., 2000], including more than 700, 000
vertebral fractures and over 300, 000 hip fractures [Riggs et al., 1995]. The probability of
death following a hip fracture in osteoporotic patients is estimated to be 10 to 20% within
the first year, and less than 50% of survivors regain their pre-fracture level of mobility and
independence [Finkelstein J.S., 2000]. Furthermore, mortality within 90 days of an
osteoporotic fracture in individuals who are older than 65 years is substantially higher than
predicted; and for a subset of these fractures the risk for early lethality increases by
approximately seven fold [Heaney, 2003]. During the past decade, the prevention of
osteoporotic fractures has been limited to the use of anti-resorptive drugs [Cranney et al.,
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2002], which have proven to be insufficient for decreasing the mortality and morbidity in
this patient population.
The known anabolic effects of parathyroid hormone (PTH) on bone formation has led to the
development of a human recombinant peptide, teriparatide (1-34 human parathyroid
hormone), corresponding to the first 34 amino acids of PTH. This drug was initially
developed to treat postmenopausal osteoporotic women to enhance bone mineral density
[Neer et al., 2001], and cortical thickness and trabecular bone volume [Jiang et al., 2005;
Kurland et al., 2000] compared to placebo controls. In addition to its anabolic effects on
bone turnover [Dempster et al., 2001; Neer et al., 2001; Rodan et al., 2000] teriparatide used
in clinical trials was shown to significantly reduce the risk of vertebral and non-vertebral
fractures in osteoporotic women [Black et al., 2003; Neer et al., 2001]. Using various animal
models, several groups have shown that intermittent exposure to PTH stimulates osteoblast
differentiation and function [Hock et al., 1992; Kulkarni et al., 2007] in vivo. In addition,
this intermittent PTH treatment was also shown to enhance fracture callus formation
[Nakazawa et al., 2005] and increase mechanical strength in adult rat fractures [Andreassen
et al., 1999; Andreassen et al., 2004] in vivo. This PTH mediated anabolic effect was
sustained throughout the remodeling phase of fracture healing [Alkhiary et al., 2005].
We hypothesized that PTH may enhance Osx expression in mesenchymal stem cells thereby
inducing their differentiation into mature osteoblasts to achieve bony union. Our data show
that daily teriparatide exposure induces Osx expression in mouse fracture callus compared to
saline controls and promotes the differentiation of bone marrow derived MSCs to the
osteoblastic lineage. We further show that intermittent PTH treatment up-regulates Osx in
osteoprogenitor cells as well as markers of osteoblast differentiation in vitro.
Materials and Methods
Animals and treatments
7–9 week old C57BL/6 mice (Jackson Labs, Bar Harbor, ME) were used for fracture
experiments. Mice were housed at the University of Rochester animal facilities according to
state and federal law requirements. The animal studies were conducted in accordance with
the principles and procedures approved by the University of Rochester IACUC. Mice were
randomly selected to control or teriparatide (a generous gift from Eli Lilly) treated groups.
Immediately following fracture experiments as described below, mice received daily
subcutaneous teriparatide 40cg/kg or saline as control for 21 days.
Fracture experiments
Groups of 6 mice were anesthetized with ketamine (60 mg/kg) and xylazine (4 mg/kg) in
normal saline via intraperitoneal injection. The femur fracture were performed using a 3-
point bending system adapted from Bonnarens and Einhorn [Bonnarens et al., 1984] and as
we have previously described [Kaback et al., 2008]. Fractures were radiographed by the
Faxitron x-ray system (Faxitron, X-ray, Wheeling, IL) under anesthesia on Days 7, 10, 14,
and 21 to monitor initial pin fixation as well as ongoing callus formation. Mice were
sacrificed 7, 10, 14, and 21 days following fracture by induction of CO2 narcosis followed
by cervical dislocation. For each experiment legs from 6 saline control mice and 6
teriparatide treated mice were harvested, and whole calluses (Including vessels, cartilage and
bone) isolated for RNA extraction prior to gene expression analyses. Another set of control
and treated mice (6 each) were used for histologic study as described below.
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Histological and histomorphometric analyses
Fractured femurs were harvested as described above, fixed in 10% formalin, decalcified in
an EDTA solution, embedded in paraffin and cut into 3 micron thick serial sections. These
sections were stained in Alcian blue/hematoxylin solution as described previously [Zhang et
al., 2002; Kaback et al., 2008]. Histomorphometric analyses were performed using the
Osteometrics software (Decatur, GA). Briefly, bone and cartilage formation was quantified
on H&E-stained sections by outlining the perimeter of the fracture callus under the 2x
objective. Areas of new woven bone and cartilage were then traced. This procedure was
repeated until the entire fracture callus has been evaluated. The areas of woven bone,
cartilage, and total fracture callus are represented in square millimeters. Data is
representative of three separate samples per group and the average total fracture callus size
determined in each group. Immunohistochemical staining for Osx was performed using a
rabbit polyclonal antibody (a generous gift from AbCam, UK) as previously described
[Kaback et al., 2008].
Cell culture
For in vitro experiments, we used primary bone marrow derived cells harvested from tibias
and femurs of mice treated daily for 7 days, via intraperitoneal injections, with 40cg/kg with
teriparatide or saline control. A 25G5/8 needle (BD biosciences, Franklin Lakes, NJ) was
used to flush the marrow with α-MEM (Gibco BRL, Grand Island, NY) containing 20%
fetal bovine serum. Marrow was filtered using a swinnex syringe filter (Millipore, Billerica,
MA) as previously described [Drissi et al., 1999]. Cells were plated in 6 well plates at the
desired density of 2 × 106 cells per well, allowed to adhere for 4 days, and then cultured in
complete media containing ascorbic acid (50cg/ml) and beta-glycerophosphate (10mM) for
7, 14 and 28 days prior to either staining or RNA harvesting.
RNA extraction and Real time RT-PCR
For our in vitro experiments, total RNA was isolated using the RNeasy Kit (Qiagen,
Valencia, CA) following the manufacturer’s recommendations. Trizol (Invitrogen, Carlsbad,
CA) was used to extract RNAs from fracture calluses according to the manufacturer protocol
for tissue extraction using a Tissue Lyser (Qiagen, Valencia, CA). For our gene expression
experiments, cDNA was synthesized using the advantage Superscript II RT-PCR kit
(Invitrogen, Carlsbad, CA), following the manufacturer recommendation. Real time RT-
PCR with specific primers for murine (Table 1) were performed using the fluorescent dye
SYBR Green I (SYBR Green PCR Master Mix, Applied Biosystems, Foster City, CA) as
previously described [Soung et al., 2007].
Statistical analysis
Statistical analyses were performed using the student t-test. Mean and standard error (SE)
were calculated using GradphPad InStat (Version 4.03, San Diego, CA). The t-test was
performed to determine which means were significantly different (p < 0.05).
Results
Teriparatide induces Osx expression in bone marrow derived stem cells while promoting
their differentiation into osteoblasts
PTH was previously shown to promote MSC differentiation into mature osteoblasts in vivo
[Nishida et al., 1994]. However, the molecular events underlying this PTH anabolic effect
on murine bone marrow derived MSCs are still unclear. We harvested bone marrow
mesenchymal progenitors from mice previously treated or not with daily teriparatide via
intra-peritoneal injections for 7 days. Flushed marrow mesenchymal cells from both groups
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were then maintained in osteogenic media for up to four weeks. Alkaline phosphatase
staining was increased upon systemic teriparatide treatment in these cells in comparison to
cells harvested from saline injected controls (data not shown). Using RNA extracted from
these cultures, we assessed mRNA levels of Osx and other osteoblast phenotypic genes.
Figure 1A shows that Osx expression is significantly and time dependently up-regulated
after 14 and 28 days of culture (2.5 and 4 fold respectively) in MSCs from mice treated with
teriparatide compared to saline controls. Similarly, Runx2 transcripts were also induced by
teriparatide treatment at 14 and 28 days in culture by approximately 2.5 fold (Figure 1B).
Figure 1D shows that while teriparatide did not induce alkaline phosphatase mRNA levels at
7 days, it strongly and significantly enhanced its transcript levels at days 14 and 28 by 15
and 8 fold respectively. Finally, transcripts of type I collagen (Figure 1C) and osteocalcin
(Figure 1E) were likewise up-regulated by 2 to 3 fold after 14 and 28 days in culture. These
results show that systemic teriparatide treatment can induce mesenchymal stem cell
differentiation into osteoblasts possibly through induction of Osx and Runx2 expression.
Teriparatide effects on fracture healing in a mouse model
Intermittent 1-34 PTH was previously shown to increase callus size and bone mineral
density in rats [Alkhiary et al., 2005; Andreassen et al., 1999]. Here we investigated the
effects of human recombinant PTH (teriparatide) on bone repair in a mouse femoral fracture
model. We first examined the effects of teriparatide on fracture healing by radiographic and
histological analyses. Saline injected animals were also used as controls. Figure 2 shows that
while at day 7 post-fracture no differences are radiographically apparent between
teriparatide and saline treated controls, the size of the radiolucent soft callus at 10 days post-
fracture in the teriparatide treated mice was increased compared to saline controls. By day
14 this difference in callus size persists in the teriparatide treated mice compared to controls
as shown by X-ray analysis (Figure 2A). Histological assessments of these fractures (Figure
2B) show that 10 days following teriparatide treatment, enhanced cartilage formation, as
evidenced by Alcian blue staining, was observed in these calluses compared to the controls.
By day 14 of treatment, increased bone formation was observed in the teriparatide treated
mice compared to the saline injected animals. Our histomorphometric measurements of
callus sizes in teriparatide treated compared to saline injected controls show that teriparatide
induced a significant increase in callus formation at 7, 10, and 14 days post fracture by 35%,
264%, and 75%, respectively (Figure 2C). These results suggest that PTH enhances fracture
healing possibly through enhanced differentiation of mesenchymal progenitor cells into
mature osteoblasts at the fracture site.
Osterix expression in the fracture calluses of teriparatide treated mice
The effects of teriparatide on fracture healing suggest the recruitment of mesenchymal
progenitor cells into the fracture site and their differentiation into mature osteoblasts. In
addition, systemic treatment of mice with teriparatide enhanced Osx expression in marrow
derived osteogenic cells (shown above in Figure 1). In order to determine the cellular
representation of Osx during fracture repair in response to teriparatide, we performed
immunohistochemical assays using an Osx specific antibody [Kaback et al., 2008]. Figure
3A shows that Osx protein is expressed in periosteal cells and confined in the immature
chondrocyte cell population while it is absent from fibrous tissue and chondrocytes
undergoing hypertrophy in the saline injected controls at day 7 post-fracture. After 10 days
of treatment, while both the saline controls and the teriparatide injected mice exhibit onset of
trabecular bone formation in the fracture calluses, the number of Osx expressing osteoblasts
and the volume of de novo trabecular bone is increased in the treated fractures compared to
controls. The expression of Osx in the fracture calluses was also evaluated after cartilage
remodeling and at the onset of bony union and trabecular bone remodeling at days 14 and
21. Fourteen days following teriparatide treatment, massive bone formation is observed and
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Osx expression is seen in the osteoblast lining cells as well as in osteocytes embedded in the
woven bone. This expression is also observed in the saline injected controls. This same
effect is seen after 21 days of treatment with an enhanced representation of trabecular bone
compared to day 14. This accelerated trabecular bone formation is also concomitant with the
absence of marrow cavities in the calluses of teriparatide treated animals compared to saline
controls. Negative controls using secondary antibody alone did not show any reactivity at all
time points (data not shown). Together, these results suggest that PTH accelerates fracture
healing through enhanced commitment of progenitor cells towards an osteoblastic
phenotype possibly through induction of Osx expression.
Systemic teriparatide treatment induces Osx and osteoblast phenotypic markers
expression in fracture calluses
Intermittent PTH systemic injection was previously shown to increase fracture callus size,
bone mineral density, and mechanical strength in rat femur fractures [Alkhiary et al., 2005].
However, the effects of daily teriparatide treatment on gene expression in fracture callus
have yet to be defined. To further investigate the molecular targets of PTH in fracture
calluses during bone repair, we performed gene expression analyses using RNAs extracted
from fracture calluses of teriparatide treated mice and saline controls at 7, 10, 14 and 21
days post-fracture. Figure 4A shows that Osx transcripts are significantly up-regulated (3
fold) in calluses isolated 10 days post-fracture in the teriparatide treated groups compared to
saline injected controls. Transcript levels continue to be elevated at 14 days post fracture in
the teriparatide treated group (1.5 fold) in comparison to the saline injected animals.
However, no difference was observed in Osx expression at 7 and 21 days post-fracture. We
also assessed the expression of the bone and cartilage related gene Runx2. Runx2 transcripts
are significantly induced at 7 days (2 fold) and 10 days following teriparatide treatment in
these fracture calluses (2.5 fold) compared to untreated controls. However, Runx2 transcript
levels are similar to saline controls 14 and 21 days post fracture (Figure 4B). Cartilage and
bone phenotypic marker gene expression was also evaluated in these calluses. Thus, while
teriparatide treatment only induces Sox9 expression in the early time point at 7 days
compared to controls (Figure 4C), type II collagen expression is first enhanced at day 7 then
inhibited at day 10 upon teriparatide treatment (Figure 4D). As expected, both control and
treated levels of the chondrocyte phenotypic genes are reduced 14 and 21 days post-fracture
when the cartilage matrix is remodeled in the fracture callus. On the other hand, type I
collagen mRNA levels were initially slightly but significantly inhibited at day 7 post-
fracture, then up-regulated between 10 and 14 days of teriparatide treatment (2 and 3 fold,
respectively), while they were thereafter down-regulated 21 days post-fracture in the
teriparatide treated groups compared to controls (by 2 fold) (Figure 4E). The marker for
matrix mineralization, osteocalcin was progressively up-regulated by 4 fold following 10
and 14 days of teriparatide treatment compared to saline controls in these fracture calluses.
After 21 days of teriparatide exposure, osteocalcin levels were enhanced 2 fold compared to
saline treated animals (Figure 4F). Together, these results indicate that daily systemic
teriparatide therapy post-fracture is not only able to up-regulate Osx transcripts in fracture
callus but also induce mesenchymal stem cell commitment towards osteogenesis in the
fracture site.
Discussion
Although the main function of PTH remains to regulate bone metabolism and maintain
calcium homeostasis [Arnaud et al., 1970], several studies have investigated its anabolic
effects in osteoporotic patients [Bilezikian et al., 2005; Black et al., 2003; Neer et al., 2001].
As fragility fractures continue to pose a unique dilemma to clinicians in terms of
understanding fracture biology as well as establishing practical pharmacological agents that
will reduce the relative risk of future fractures, the anabolic effects of PTH were also
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investigated during bone repair both in clinical trials and using animal models [Alkhiary et
al., 2005; Jiang et al., 2005; Neer et al., 2001]. Previously, a fracture prevention trial
established the role of teriparatide as an anabolic agent capable of reducing the risk of
fragility fractures in postmenopausal women [Black et al., 2003; Neer et al., 2001].
However, a possible role for teriparatide in enhancing bony union of post-traumatic fractures
should be postulated. Here we report the effects of teriparatide on bone repair in a mouse
fracture model. We examined the cellular and molecular pathways underlying PTH
enhancement of fracture healing. We believe that one possible mechanism by which PTH
mediates fracture repair is through up-regulation of the zinc finger transcription factor Osx
in mesenchymal stem cells, which in turn stimulates their recruitment and differentiation
into mature osteoblasts.
Previous studies have described antagonistic effects of PTH on bone formation upon its
mode of administration in vitro and in vivo [Alkhiary et al., 2005; Andreassen et al., 1999;
Andreassen et al., 2004; Black et al., 2003; Jiang et al., 2005; Nakazawa et al., 2005; Neer et
al., 2001; Thomas, 2006]. While continuous exposure to PTH leads to massive bone loss in
vivo through increased osteoclast mediated bone resorption following enhanced osteoclast
density and activity [Hadjidakis et al., 2006; Potts, 2005], Ishizuya and colleagues
demonstrated the ability of PTH treatment administered under an intermittent regimen to
induce bone formation through enhanced alkaline phosphatase activity, calcium content and
the number of mineralized bone nodules deposited by rat calvaria-derived osteoprogenitor
cells in vitro [Ishizuya et al., 1997]. Here we show that intermittent exposure of
osteoprogenitor cells to PTH enhances Osx expression and promotes osteoblast
differentiation.
The cellular events required for proper fracture healing of long bones through endochondral
ossification are well documented [Ferguson et al., 1999; Gerstenfeld et al., 2003; Vortkamp
et al., 1998]. Systemic and growth factors are produced in response to skeletal injury leading
to the recruitment of progenitor cells from both the bone marrow as well as the periosteum
to the site of injury [Hiltunen et al., 1993]. Several investigations reported the requirement
for factors including the TGF-β superfamily, the PDGF, FGF, Ihh, prostaglandins, Wnt and
VEGF during fracture repair [Gerstenfeld et al., 2003] yet very limited information is
available about the mechanisms of action of their downstream targets in fracture calluses.
Therefore, we addressed the molecular aspects of mesenchymal stem cell recruitment and
differentiation that mediate fracture healing in response to PTH using an animal mouse
model. We found that teriparatide increases cartilage and bone formation in the fracture
callus at 7 and 10 days post-fracture.
Our assessment of gene expression in the fracture calluses in response to teriparatide shows
that Osx expression was up-regulated in the fracture callus following treatment compared to
saline injected controls. These results clearly suggest a correlation between PTH enhanced
fracture repair and the known Osx mediated commitment of MSCs to the osteoblastic
phenotype. We found that while markers of chondrocyte maturation are decreased as the
fracture calluses ossify, osteoblast differentiation markers be induced. However, the
inductive effects of teriparatide on Sox9 and type II collagen gene expression 7 days post-
facture suggest a positive effect on chondrogenesis. Although, chondrocytes exhibit
receptors for PTHrP, the effects of PTH on chondrogenesis are not known. These effects
may also be indirect. Finally, although the effects of teriparatide on type I collagen gene
expression were inductive in the fracture callus between 10 and 14 days post-fracture, PTH
treatment inhibited type I collagen expression three weeks following treatment. This could
be attributed to enhanced osteoblast maturation in the fracture callus as evidenced by the
significant increase in osteocalcin expression at day 21. However, at day 7 post-fracture,
teriparatide also inhibited type I collagen expression which in combination with its effects
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on Sox9 and type II collagen further suggests an effect of PTH on chondrogenesis during
fracture healing.
In addition to its role in mediating bi-potent mesenchymal progenitor cell commitment
toward osteogenesis [Nakashima et al., 2002], we have recently reported that Osx not only
mediates MSC differentiation into mature osteoblasts but also strongly inhibits chondrocyte
maturation [Kaback et al., 2008]. Our present study demonstrates that systemic treatment of
these mice with teriparatide not only enhanced mesenchymal progenitor cell differentiation
into mature osteoblasts, but also increased Osx expression in these marrow derived cells
isolated from teriparatide treated mice in vivo. This increase in Osx expression along with
osteoblastic phenotypic markers was concomitant with Runx2 expression. Our results
demonstrate that systemic teriparatide treatment was able to induce Runx2 levels in the
callus in the early time points following fracture healing. It is however noteworthy that
Runx2 levels were not induced after day 10 when cartilage is replaced with bone in the
callus, while Osx levels were still upregulated. While this shift is Osx versus Runx2
expression during callus formation and remodeling may be in support of the dogma of Osx
being downstream of Runx2, it is not clear why PTH did not continue to induce Runx2
expression when cartilage is replaced with bone.
Previous evidence attributed the anabolic effects of PTH on bone formation to the induction
of Runx2 [Krishnan et al., 2003]. The anabolic effects of PTH on bone formation were
previously attributed to the increased expression of Runx2 through the PKA pathway
[Krishnan et al., 2003]. The genetic evidence provided by the loss of Osx or Runx2 function
suggested that Osx may be downstream of Runx2. We have previously shown that Osx may
be a direct downstream target of Runx2 in various cell lines [Nishio et al., 2006]. However,
emerging evidence in recent studies also advocate a Runx2 independent activation of Osx
gene expression [Lee et al., 2003; Nakashima et al., 2003; Tu et al., 2006; van der et al.,
2005]. It is possible that while PTH targets both Runx2 and Osx, its effects may be directly
mediated through Osx and independently from Runx2. Further studies will delineate the
precise role of Osx in mesenchymal stem cell recruitment to the fracture site in response to
PTH treatment. Together, our findings bring novel insight into the cellular and molecular
pathways underlying PTH mediated fracture repair thereby supporting its use not only as an
anabolic agent for postmenopausal/osteoporotic bone loss but also for skeletal tissue repair
and bone regeneration.
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Figure 1. Teriparatide induces bone marrow derived mesenchymal stem cell differentiation into
osteoblasts
Bone marrow derived progenitor cells were isolated from femurs of mice previously injected
daily with teriparatide or saline solution for 7 days. Cells were cultured for 7, 14, and 28
days for total RNA analysis. mRNA levels of Osx (A), Runx2 (B), type I collagen (C),
alkaline phosphatase (D), and osteocalcin (E) were measured using real time RT-PCR.
Values, which are normalized to β actin, are expressed as means ± SE (n=3). * denotes
statistical significance from controls at each time point (p<0.05).
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Figure 2. Teriparatide accelerates femur fracture repair
7–9 week old C57BL/6 mice underwent unilateral femur fractures and were subsequently
injected with daily teriparatide (lower panels) or saline solution (upper panels) as described
in the Methods section. X-rays (A), histology (B), and histomophometric analysis (C) were
performed 7, 10, and 14 days post-fracture. Values are expressed as means ± SE (n=3). *
denotes statistical significance from controls at each time point (p<0.05).
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Figure 3. The effects of teriparatide on Osx protein expression during fracture repair
7–9 week old C57BL/6 mice underwent unilateral femur fractures and were subsequently
injected daily with teriparatide (right panels; x10 and x40) or saline solution (left panels;
x10 and x40) as described in the Methods section. Osx proteins were detected in the fracture
callus at day 7, 10, 14, and day 21 post-fracture using immunohistochemical analysis. Of
note is the strong immunostaining in the progenitor cells (arrows) as well as osteoblasts (*)
and osteocytes (@) seen in newly formed bone. In addition, there is a lack of staining in the
hypertrophic chondrocytes (#).
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Figure 4. Teriparatide increases Osx transcript expression in mouse callus during fracture
healing
7–9 week old C57BL/6 mice underwent unilateral femur fractures and received daily
injection of teriparatide or saline solution for 7 to 21 days. Fracture calluses at various
healing time points (7, 10, 14, and 21 days post fracture) were collected and total RNA
extracted. mRNA levels of Osx (A), Runx2 (B), Sox9 (C), type II collagen (D), type 1
collagen (E), and osteocalcin (F) were measured using real time RT-PCR. Values are
expressed as means ± SE (n=3), normalized to β-actin. * denotes statistical significance
from saline controls at each time point (p<0.05).
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TABLE 1
Primers used for real-time RT-PCR experiments
Genes Forward primer Reverse primer Accession #
Runx2 CCGGGAATGATGAGAACTA ACCGTCCACTGTCACTTT D14636
Osterix ACTGGCTAGGTGGTGGTCAG GGTAGGGAGCTGGGTTAAGG AY803733
Sox9 AGGAAGCTGGCAGACCAGTA CGTTCT TCACCGACT TCCTC AF421878
Type II collagen ACTGGTAAGTGGGGCAAGAC CCACACCAAATTCCTGTTCA BC 052326
Alkaline phosphatase TGACCTTCTCTCCTCCATCC CTTCCTGGGAGTCTCATCCT NM007431
Type I collagen TGTCCCAACCCCCAAAGAC CCCTCGACTCCTACATCTTCTGA NM007742.2
Osteocalcin TGCTTGTGACGAGCTATCAG GAGGACAGGGAGGATCAAGT L24431
β-Actin-F AGATGTGGATCAGCAAGCAG GCGCAAGTTAGGTTTTGTCA NM007393
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